Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Response rate · women with recurrent epithelial ovarian cancer

It is very uncertain whether weekly paclitaxel changes response rate compared with three‐weekly paclitaxel (very low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.07 [0.78, 1.48]
2 studies · 263 participants
Very low

Response rate ‐ platinum‐sensitive · women with recurrent epithelial ovarian cancer

It is very uncertain whether weekly paclitaxel changes response rate ‐ platinum‐sensitive compared with three‐weekly paclitaxel (very low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.13 [0.77, 1.65]
2 studies · 100 participants
Very low

Response rate ‐ platinum‐resistant · women with recurrent epithelial ovarian cancer

It is very uncertain whether weekly paclitaxel changes response rate ‐ platinum‐resistant compared with three‐weekly paclitaxel (very low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.01 [0.55, 2.12]
2 studies · 163 participants
Very low